Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:08Z | |
dc.date.available | 2018-06-22T09:54:08Z | |
dc.date.issued | 2011 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42204 | |
dc.description.abstract | The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays more common in families. The most frequent malignancies diagnosed during pregnancy are breast cancer, cervical cancer, haematological malignancies (lymphomas and acute leukaemias) and melanoma. Less common tumours are gastrointestinal, urological and lung cancers [1]. © 2011 Elsevier Ltd. | en |
dc.language.iso | eng | en |
dc.source | European journal of cancer | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Chlormethine | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Dacarbazine | en |
dc.subject | Dactinomycin | en |
dc.subject | Daunorubicin | en |
dc.subject | Doxorubicin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Hydroxyurea | en |
dc.subject | Methotrexate | en |
dc.subject | Neoplasms | en |
dc.subject | Prednisone | en |
dc.subject | Procarbazine | en |
dc.subject | Tamoxifen | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Ovary cancer | en |
dc.subject | Priority journal | en |
dc.subject | Drug safety | en |
dc.subject | Monotherapy | en |
dc.subject | Navelbine | en |
dc.subject | Oxaliplatin | en |
dc.subject | Taxane derivative | en |
dc.subject | Platinum | en |
dc.subject | Erlotinib | en |
dc.subject | Lung cancer | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy complications | en |
dc.subject | Pregnant woman | en |
dc.subject | Systemic therapy | en |
dc.subject | Pregnancy | en |
dc.subject | Acute granulocytic leukemia | en |
dc.subject | Acute lymphoblastic leukemia | en |
dc.subject | Busulfan | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Chronic myeloid leukemia | en |
dc.subject | Down syndrome | en |
dc.subject | Fetus death | en |
dc.subject | Hodgkin disease | en |
dc.subject | Hypospadias | en |
dc.subject | Idarubicin | en |
dc.subject | Imatinib | en |
dc.subject | Meningocele | en |
dc.subject | Nonhodgkin lymphoma | en |
dc.subject | Pregnancy complication | en |
dc.subject | Promyelocytic leukemia | en |
dc.subject | Pylorus stenosis | en |
dc.subject | Spontaneous abortion | en |
dc.subject | Unindexed drug | en |
dc.subject | Bicuspid aortic valve | en |
dc.subject | Brain tumor | en |
dc.subject | Clubfoot | en |
dc.subject | Colorectal cancer | en |
dc.subject | Folinic acid | en |
dc.subject | Lapatinib | en |
dc.subject | Melanoma | en |
dc.subject | Neoplasm | en |
dc.subject | Oligohydramnios | en |
dc.subject | Preeclampsia | en |
dc.subject | Respiratory distress | en |
dc.subject | Sarcoma | en |
dc.subject | Syndactyly | en |
dc.subject | Trastuzumab | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Vesicoureteral reflux | en |
dc.subject | Hypertension | en |
dc.subject | Side effect | en |
dc.subject | Prematurity | en |
dc.subject | Cancer hormone therapy | en |
dc.subject | Respiratory failure | en |
dc.subject | Attitudes | en |
dc.subject | Rituximab | en |
dc.subject | Head and neck cancer | en |
dc.subject | Anthracycline | en |
dc.subject | Health knowledge | en |
dc.subject | Practice | en |
dc.subject | Kidney failure | en |
dc.subject | Brain ventricle dilatation | en |
dc.subject | Developmental disorder | en |
dc.subject | Ectopic pregnancy | en |
dc.subject | Hydramnios | en |
dc.subject | Intrauterine growth retardation | en |
dc.subject | Medical oncology | en |
dc.subject | Pregnant women | en |
dc.subject | Premature fetus membrane rupture | en |
dc.subject | Unplanned pregnancy | en |
dc.subject | Vagina bleeding | en |
dc.title | Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer? | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(11)70199-X | |
dc.description.volume | 47 | |
dc.description.issue | SUPPL. 3 | en |
dc.description.startingpage | S348 | |
dc.description.endingpage | S352 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |